Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Peripheral nerves regenerate at roughly 1 mm per day under optimal conditions, so protocols for neuropathy tend to be longer than those for acute injuries
The dynamics of BPC are not well understood, including where it goes, how it works, and its effects, such as the results of 80mg enemas of BPC for colitis, although phase one and two trials showed no adverse effects and a positive signal for ulcer colitis, respectively 1m4s
Australia Research on a protective protein in human stomach juice led to the discovery of BPC-157
TB-500 works more broadly on actin regulation and systemic tissue remodeling
